Breaking News Instant updates and real-time market news.

ESTA

Establishment Labs

$23.15

0.07 (0.30%)

08:04
08/13/19
08/13
08:04
08/13/19
08:04

Establishment Labs reports Q2 EPS (44c), consensus (53c)

Reports Q2 revenue $21.7M, consensus $20.64M. "During the second quarter, we continued to prove the strength of our Women's Health story, driving strong sales growth of over 58%, while regulatory agencies worldwide are placing restrictions on the rest of the industry," said Juan Jose Chacon-Quiros, Chief Executive Officer of Establishment Labs. "We believe this growth trajectory speaks to the clear differentiation and improved safety and aesthetic outcomes of our product portfolio, as well as to the effectiveness of the direct sales force model that we have implemented in Europe and Brazil. In parallel with our ongoing research and development activities, our U.S. FDA clinical trial is progressing with all surgeries now complete in the primary and revision augmentation cohorts and enrollment continuing in the reconstruction cohorts. Importantly, we are implementing a bifurcation strategy in the U.S. that will allow us to submit for the aesthetic cohorts sooner while pursuing approval for the reconstruction cohorts separately. I am very pleased with our progress to this point and I look forward to a strong second half of the year."

  • 13

    Aug

  • 09

    Sep

  • 13

    Nov

ESTA Establishment Labs
$23.15

0.07 (0.30%)

07/11/19
JEFF
07/11/19
NO CHANGE
Target $40
JEFF
Buy
Australia implants decision a 'big positive' for Establishment, says Jefferies
After Australia's Therapeutic Goods Administration proposed to cancel or suspend use of textured breast implants, concluding that these devices are associated with a higher rate of anaplastic large cell lymphoma, or ALCL, Jefferies analyst Raj Denhoy called the decision a "big positive" for Establishment Labs (ESTA). The decision is still in the proposal stage, but Establishment is the only manufacturer with products approved in Australia that is not on the list, which proposes to ban implants from Allergan (AGN), J&J's (JNJ) Mentor and other manufacturers, according to Denhoy. He keeps a Buy rating and $40 price target on shares of Establishment Labs.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
07/12/19
WELS
07/12/19
NO CHANGE
Target $29
WELS
Outperform
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
Wells Fargo analyst David Maris believes Australia's proposal to ban, suspend or impose strict restrictions on a number of textured implants from Allergan (AGN), Johnson & Johnson (JNJ) and other smaller manufacturers is "excellent news" for Establishment Labs Holdings (ESTA). The move by Australia's regulatory body Therapeutic Goods Administration will help solidify Establishment's reputation for safety as the company's Motiva brand is the only listed company without any restricted brands, Maris tells investors in a research note. Further, Australia is a highly regulated and developed market, so the ban could help shift market share in other geographies outside of the county as well, contends the analyst. Maris reiterates an Outperform rating on Establishment Labs with a $29 priced target. The stock closed yesterday up $1.54 to $22.44.
07/24/19
WELS
07/24/19
NO CHANGE
WELS
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
Wells Fargo analyst David Maris says Allergan (AGN) recalling worldwide its textured implants after Canada, France, and Australia removed them from the market is not unexpected. The company's total sales in 2018 were approximately $15.8B, with breast implants approximately $263M and textured breast implants $26M, Maris tells investors in a research note. He views the recall as "clearly good" for Establishment Labs (ESTA) and Sientra (SIEN), "which have not been implicated." Maris thinks both companies will continue to gain market share due to the recall.

TODAY'S FREE FLY STORIES

DK

Delek US

$33.35

0.555 (1.69%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$30.14

4.165 (16.04%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$30.81

0.315 (1.03%)

, MSFT

Microsoft

$138.77

1.52 (1.11%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Initiation
Slack Technologies, Microsoft initiated  »

Slack Technologies…

WORK

Slack Technologies

$30.81

0.315 (1.03%)

MSFT

Microsoft

$138.77

1.52 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

MSGN

MSG Networks

$14.78

-2.07 (-12.28%)

07:21
08/22/19
08/22
07:21
08/22/19
07:21
Recommendations
MSG Networks analyst commentary  »

MSG Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$103.11

17.54 (20.50%)

07:19
08/22/19
08/22
07:19
08/22/19
07:19
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

MSG

Madison Square Garden

$260.99

-6.38 (-2.39%)

07:19
08/22/19
08/22
07:19
08/22/19
07:19
Initiation
Madison Square Garden initiated  »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$108.00

9.96 (10.16%)

07:16
08/22/19
08/22
07:16
08/22/19
07:16
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 20

    Nov

COO

Cooper Companies

$332.66

0.39 (0.12%)

, ESLOY

EssilorLuxottica

$0.00

(0.00%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Cooper Companies, EssilorLuxottica analyst commentary  »

Cooper Companies price…

COO

Cooper Companies

$332.66

0.39 (0.12%)

ESLOY

EssilorLuxottica

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 04

    Sep

CERN

Cerner

$71.77

0.44 (0.62%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Upgrade
Cerner rating change  »

Cerner upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

TGT

Target

$103.11

17.54 (20.50%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

SLM

Sallie Mae

$8.29

0.07 (0.85%)

07:11
08/22/19
08/22
07:11
08/22/19
07:11
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ORBC

Orbcomm

$4.84

-0.055 (-1.12%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Upgrade
Orbcomm rating change  »

Orbcomm upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Hot Stocks
Clearside Biomedical plans to resubmit XIPERE NDA in 1Q20 »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RCKT

Rocket Pharmaceuticals

$11.44

0.115 (1.02%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Hot Stocks
Rocket Pharmaceuticals announces clearance to commence Phase 2 FANCOLEN-II trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

HIW

Highwoods Properties

$43.92

0.14 (0.32%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Conference/Events
Highwoods Properties to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

MYGN

Myriad Genetics

$25.12

0.67 (2.74%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
Myriad 'applauds' USPSTF recommendation on BRCA-related cancer prevention »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 13

    Nov

KSHB

KushCo Holdings

$0.00

(0.00%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
KushCo Holdings secures $50M credit facility from Monroe Capital »

KushCo Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$17.39

0.3 (1.76%)

07:07
08/22/19
08/22
07:07
08/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Retrophin »

Retrophin down 25% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRAX

Social Reality

$3.39

-0.06 (-1.74%)

07:06
08/22/19
08/22
07:06
08/22/19
07:06
Hot Stocks
Social Reality changing name to SRAX August 26th »

SRAX will formally change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLHF

Standard Lithium

$0.00

(0.00%)

07:05
08/22/19
08/22
07:05
08/22/19
07:05
Hot Stocks
Standard Lithium completes fabrication of Phase 1, 2 of 'LiSTR' plant »

Standard Lithium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLY

Fly Leasing

$18.25

0.265 (1.47%)

07:04
08/22/19
08/22
07:04
08/22/19
07:04
Hot Stocks
Fly Leasing CEO says 'FLY continues to achieve record results' »

"FLY continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

WDAY

Workday

$190.87

4.53 (2.43%)

, CRM

Salesforce

$147.40

1.85 (1.27%)

07:04
08/22/19
08/22
07:04
08/22/19
07:04
Initiation
Workday, Salesforce initiated  »

Workday initiated with a…

WDAY

Workday

$190.87

4.53 (2.43%)

CRM

Salesforce

$147.40

1.85 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 12

    Dec

  • 16

    Dec

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:03
08/22/19
08/22
07:03
08/22/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Clearside Biomedical »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

FLY

Fly Leasing

$18.25

0.265 (1.47%)

07:03
08/22/19
08/22
07:03
08/22/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Fly Leasing »

Fly Leasing board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

USNA

Usana

$67.47

0.43 (0.64%)

07:02
08/22/19
08/22
07:02
08/22/19
07:02
Initiation
Usana initiated  »

Usana initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.